X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (132) 132
Patent (20) 20
Publication (10) 10
Magazine Article (6) 6
Book / eBook (1) 1
Book Review (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (20) 20
article (18) 18
humans (18) 18
melanoma (13) 13
melanoma - drug therapy (13) 13
melanoma - genetics (12) 12
proto-oncogene proteins b-raf - antagonists & inhibitors (12) 12
cell line, tumor (11) 11
mutation (11) 11
proto-oncogene proteins b-raf - genetics (11) 11
vemurafenib (10) 10
chemistry (9) 9
metallurgy (9) 9
drug resistance, neoplasm - genetics (8) 8
human necessities (8) 8
hygiene (8) 8
medical or veterinary science (8) 8
melanoma - pathology (8) 8
antineoplastic agents - therapeutic use (7) 7
beer (7) 7
biochemistry (7) 7
cancer (7) 7
enzymology (7) 7
microbiology (7) 7
mutation or genetic engineering (7) 7
proto-oncogene proteins b-raf - metabolism (7) 7
spirits (7) 7
vinegar (7) 7
wine (7) 7
animals (6) 6
compositions thereof (6) 6
culture media (6) 6
female (6) 6
indoles - pharmacology (6) 6
melanoma - metabolism (6) 6
mice (6) 6
microorganisms or enzymes (6) 6
mutations (6) 6
oncology (6) 6
propagating, preserving or maintaining microorganisms (6) 6
protein kinase inhibitors - therapeutic use (6) 6
sulfonamides - pharmacology (6) 6
acquired-resistance (5) 5
braf (5) 5
cell biology (5) 5
cells (5) 5
drug resistance, neoplasm - drug effects (5) 5
male (5) 5
map kinase signaling system - drug effects (5) 5
measuring (5) 5
middle aged (5) 5
physics (5) 5
protein kinase inhibitors - pharmacology (5) 5
research (5) 5
resistance (5) 5
skin neoplasms - drug therapy (5) 5
skin neoplasms - genetics (5) 5
specific therapeutic activity of chemical compounds ormedicinal preparations (5) 5
testing (5) 5
aged (4) 4
compositions or test papers therefor (4) 4
condition-responsive control in microbiological orenzymological processes (4) 4
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (4) 4
indoles - therapeutic use (4) 4
investigating or analysing materials by determining theirchemical or physical properties (4) 4
measuring or testing processes involving enzymes, nucleicacids or microorganisms (4) 4
metastasis (4) 4
metastatic melanoma (4) 4
multidisciplinary sciences (4) 4
preparations for medical, dental, or toilet purposes (4) 4
processes of preparing such compositions (4) 4
raf inhibition (4) 4
sulfonamides - therapeutic use (4) 4
survival (4) 4
tumors (4) 4
adult (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic agents - pharmacology (3) 3
b-raf (3) 3
base sequence (3) 3
biochemistry & molecular biology (3) 3
blasting (3) 3
braf inhibition (3) 3
care and treatment (3) 3
drug resistance (3) 3
drug therapy (3) 3
enzyme activation - drug effects (3) 3
extracellular signal-regulated map kinases - metabolism (3) 3
gene expression regulation, neoplastic (3) 3
gene mutations (3) 3
heating (3) 3
hek293 cells (3) 3
kinases (3) 3
lighting (3) 3
mechanical engineering (3) 3
mek (3) 3
mek inhibitors (3) 3
melanoma - enzymology (3) 3
neoplasms (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2016, Volume 375, Issue 9, pp. 819 - 829
Journal Article
Cancer Research, ISSN 0008-5472, 08/2011, Volume 71, Issue 15, pp. 5067 - 5074
(V600E)B-RAF mutation is found in 50% to 60% of melanomas, and the novel agents PLX4032/vemurafenib and GSK2118436 that inhibit the (V600E)B-RAF kinase achieve... 
Apoptosis - drug effects | Humans | Multiprotein Complexes | Neoplasm Proteins - physiology | Recombinant Fusion Proteins - physiology | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Receptor, Platelet-Derived Growth Factor beta - genetics | Quinolines - pharmacology | Mechanistic Target of Rapamycin Complex 1 | Receptor, Platelet-Derived Growth Factor beta - antagonists & inhibitors | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Spheroids, Cellular - drug effects | MAP Kinase Kinase Kinases - antagonists & inhibitors | Proteins - physiology | Transcription Factors - physiology | Receptor, Platelet-Derived Growth Factor beta - physiology | Morpholines - pharmacology | Transcription Factors - antagonists & inhibitors | Imidazoles - pharmacology | Proto-Oncogene Proteins c-akt - physiology | Melanoma - pathology | Sulfonamides - pharmacology | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Point Mutation | Vemurafenib | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Phosphatidylinositol 3-Kinases - physiology | Signal Transduction - physiology | TOR Serine-Threonine Kinases | Drug Resistance, Neoplasm - physiology | Proteins - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Drug Resistance, Neoplasm - drug effects | Drug Screening Assays, Antitumor | Index Medicus | vemurafenib | targeted therapy | melanoma | AKT | B-RAF | acquired resistance
Journal Article
Nature, ISSN 0028-0836, 12/2010, Volume 468, Issue 7326, pp. 973 - 977
Journal Article
Nature, ISSN 0028-0836, 04/2015, Volume 520, Issue 7547, pp. 368 - 372
Drug resistance invariably limits the clinical efficacy of targeted therapy with kinase inhibitors against cancer(1,2). Here we show that targeted therapy with... 
CNS CELL-TYPES | MELANOMA | METASTASIS | MICROENVIRONMENT | TRANSLATIONAL PROFILING APPROACH | MULTIDISCIPLINARY SCIENCES | RAF INHIBITOR RESISTANCE | ACQUIRED-RESISTANCE | KINASE INHIBITORS | DRUG-RESISTANCE | CANCER CHEMORESISTANCE | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Clone Cells - drug effects | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Proto-Oncogene Proteins c-fos - deficiency | Adenocarcinoma - metabolism | Neoplasm Metastasis - drug therapy | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Proto-Oncogene Proteins c-akt - metabolism | Melanoma - metabolism | Tumor Microenvironment - drug effects | Cell Survival - drug effects | Melanoma - pathology | Down-Regulation - drug effects | Enzyme Activation - drug effects | Adenocarcinoma - drug therapy | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Cell Movement - drug effects | Lung Neoplasms - secretion | Melanoma - secretion | Animals | Clone Cells - pathology | Metabolome - drug effects | Signal Transduction - drug effects | Neoplasm Metastasis - pathology | Protein Kinase Inhibitors - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adenocarcinoma - secretion | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Pharmaceutical research | Care and treatment | Oncology, Experimental | Dosage and administration | Research | Drug therapy | Drug resistance | Antineoplastic agents | Tumors | Cancer | Melanoma | Mutation | Metastasis | Kinases | Cancer therapies | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 3, pp. 207 - 215
Journal Article
Nature Communications, ISSN 2041-1723, 2014, Volume 5, Issue 1, pp. 5712 - 5712
Increased expression of the Microphthalmia-associated transcription factor (MITF) contributes to melanoma progression and resistance to BRAF pathway... 
BRAF INHIBITION | TYROSINE KINASE AXL | RAF INHIBITION | CELLS | BREAST-CANCER METASTASIS | MULTIDISCIPLINARY SCIENCES | ACQUIRED-RESISTANCE | IMPROVED SURVIVAL | MEK INHIBITORS | UP-REGULATION | CONFERS RESISTANCE | Prognosis | Skin Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | Extracellular Signal-Regulated MAP Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - genetics | Melanoma - genetics | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Indoles - pharmacology | Pyrimidinones - pharmacology | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Proto-Oncogene Proteins B-raf - metabolism | Melanoma - metabolism | Proto-Oncogene Proteins - metabolism | Skin Neoplasms - pathology | Proto-Oncogene Proteins - antagonists & inhibitors | Microphthalmia-Associated Transcription Factor - metabolism | Signal Transduction | Proto-Oncogene Proteins - genetics | Imidazoles - pharmacology | Melanoma - pathology | Pyrimidines - pharmacology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Skin Neoplasms - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Receptor Protein-Tyrosine Kinases - genetics | Proto-Oncogene Proteins B-raf - genetics | Aminopyridines - pharmacology | Melanoma - drug therapy | Skin Neoplasms - genetics | Cell Line, Tumor | Oximes - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Microphthalmia-Associated Transcription Factor - genetics | Pyridones - pharmacology | Index Medicus
Journal Article
Angewandte Chemie - International Edition, ISSN 1433-7851, 03/2013, Volume 52, Issue 12, pp. 3379 - 3383
Journal Article
Cell, ISSN 0092-8674, 03/2016, Volume 165, Issue 1, pp. 35 - 44
Journal Article
Journal Article